Merck & Co., Inc. (NYSE: MRK) reported earnings and sales for the second quarter of 2021. Worldwide sales edged up 22% year-over-year
Merck & Company Inc.
-(MRK)
XNYS:MRK
Earnings calendar for the week of July 26
After showing weakness at the beginning of the week, benchmark stock indexes made steady gains even as economic recovery gathered steam. On
Is Merck (MRK) stock still a buy after losing the vaccine race?
After bringing the global economy to a grinding halt, the coronavirus pandemic is subsiding in most regions, thanks to the mass production
Earnings calendar for the week of May 10
Stock markets rallied amid mixed cues on the health of the labor market, with latest data showing that payrolls grew at a
Merck & Co., Inc. (MRK) Q1 2021 Earnings Call Transcript
Merck & Co., Inc. (NYSE: MRK) Q1 2021 earnings call dated Apr. 29, 2021 Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Kenneth
Earnings calendar for the week of April 26
Investor sentiment was hit by the government's proposal to levy higher capital gain tax on wealthy individuals, and the market shifted to
Merck & Co Inc (MRK) Q4 2020 Earnings Call
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C.
Merck & Co Inc (MRK) Q4 2020 Earnings Call Transcript
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum -- Vice President, Investor
Infographic: Highlights of Merck & Co. (MRK)Q4 2020 earnings report
Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged up 5%
Where do these companies stand in the COVID-19 vaccine race?
After the struggle with the COVID-19 pandemic and its impacts clouding most of 2020, the rollout of vaccines against COVID-19 is the
Earnings calendar for the week of February 1
In a week that saw one of the worst stock selloffs, Gamestop came under spotlight after the stock experienced unprecedented fluctuations, marked
Merck (MRK) pulls out of the COVID-19 vaccine race; will focus on investigational therapeutic candidates
Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical trials yielded
Merck (MRK) acquires OncoImmune to add another drug to its COVID-19 pipeline
Merck (NYSE: MRK) announced the acquisition of privately-held biopharma company OncoImmune for an upfront payment of $425 million in cash with subsequent
Merck & Co. Inc. (MRK) Q3 2020 Earnings Call Transcript
Merck & Co. Inc. (NYSE: MRK) Q3 2020 earnings call dated Oct. 27, 2020 Corporate Participants: Peter Dannenbaum -- Vice President, Investor Relations Kenneth
Infographic: Highlights of Merck & Co. (MRK) Q3 2020 earnings report
Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings and sales for the third quarter of 2020. The company's stock
Merck & Co., Inc. (MRK) Q2 2020 Earnings Call Transcript
Merck & Co., Inc. (NYSE: MRK) Q2 2020 earnings call dated July 31, 2020 https://youtu.be/kKm2dyqbeW0 Corporate Participants: Peter Dannenbaum -- Vice President of Investor
Merck (MRK) sales decline 8% in Q2 2020; raises FY20 outlook
Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of $10.9 billion
Merck & Co (NYSE: MRK) Q1 2020 Earnings Call Transcript
Merck & Co (MRK) Q1 2020 earnings call dated April 28, 2020 Corporate Participants: Peter Dannenbaum -- Vice President of Investor Relations Kenneth C.
Merck (MRK) Q1 Earnings: Key quarterly numbers that you need to note down
Merck (NYSE: MRK) today reported first quarter financial results for the period ended March 31, 2020. On GAAP basis, first quarter EPS
Merck & Co Inc (NYSE: MRK) Q4 2019 Earnings Call Transcript
Merck & Co Inc (NYSE: MRK) Q4 2019 Earnings Conference Call February 05, 2020 Corporate Participants: Peter Dannenbaum -- Vice President of Investor Relations
Merck & Co. (MRK) Q4 earnings beat estimates, revenue slightly misses
Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings for the fourth quarter of 2019. However, the company's sales slightly